Program
Human Dopaminergic Progenitor Cells
Its studies are mostly in Parkinson Disease · Multiple System Atrophy · Parkinsonian Disorders, led by iRegene Therapeutics.
Furthest: phase 2, since Nov 24, 20235 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| iRegene Therapeutics | 55 open or running | phase 2since Nov 24, 2023 | Nov 24, 2023 | Dec 2026phase 2 · NCT07028632 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 24, 2023First study: phase 2 study in Parkinson DiseaseFirst studyNCT06167681 · 40 planned · China
- Sep 14, 2024Phase 1 study in Parkinsonian DisordersNCT06608355 · 6 planned · China
- Jun 11, 2025Phase 2 study in Parkinson DiseaseNCT07028632 · 30 planned · China
- Jul 28, 2025Phase 2 study in Parkinson DiseaseNCT07102342 · 5 planned · United States
- Nov 26, 2025Phase 1 study in Multiple System Atrophy - Parkinsonian Subtype (MSA-P)NCT07289477 · 9 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Parkinson DiseaseNCT07028632
- Sep 2027Primary completion: phase 2 study in Parkinson DiseaseNCT07102342
- Oct 2027Primary completion: phase 1 study in Multiple System Atrophy - Parkinsonian Subtype (MSA-P)NCT07289477
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07289477Multiple System Atrophy - Parkinsonian Subtype (MSA-P) · China | 1 | Recruiting | Oct 2027 | 9 |
| NCT07102342Parkinson Disease · United States | 2 | Recruiting | Sep 2027 | 5 |
| NCT07028632Parkinson Disease · China | 2 | Not yet recruiting | Dec 2026 | 30 |
| NCT06608355Parkinsonian Disorders · China | 1 | Recruiting | Apr 2026 | 6 |
| NCT06167681Parkinson Disease · China | 2 | Recruiting | Dec 2025 | 40 |
How it is read
Names in the registry
- “Human Dopaminergic Progenitor Cells”, 5 entries
Conditions, from the studies’ own filings
- Parkinson Disease, 3 studies
- Multiple System Atrophy, 1 study
- Parkinsonian Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.